Clinical Trial Update: PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating AEVI-001 for ADHD in children and adolescents without mGluR mutations has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• AEVI-001 (null)

Snippet

Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-07-16